Article

Blood-Based Proteomic Test for NSCLC Will Be Reimbursed by UnitedHealthcare

The diagnostic test, developed by Biodesix, Inc, will help guide treatment decisions in patients with advanced lung cancer.

Biodesix, Inc, today announced that its VeriStrat test received a positive coverage decision from UnitedHealthcare, one of the largest commercial insurance companies in the US, with a published 44.7 million covered lives. In its Medical Policy, UnitedHealthcare describes VeriStrat as “…proven for guiding treatment decisions in patients with advanced non-small cell lung cancer (NSCLC).”

VeriStrat, included in the standard of care guidelines, is a blood-based proteomic test that provides physicians with prognostic and predictive information that helps guide treatment of advanced NSCLC. Patients with a VeriStrat Poor test result have a shorter median overall survival than those with a VeriStrat Good result. Understanding the patient’s disease state can help inform physicians’ decisions on chemotherapy, palliative care or clinical trials.

Read the complete news release on Yahoo!: http://yhoo.it/1HcbqFK

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Videos
Dr Ibrahim Aldoss
Dr John Mascarenhas
5 experts are featured in this series
4 experts in this video
5 experts are featured in this series
4 experts in this video
1 expert is featured in this series.
CK Wang, MD, COTA
Dr Pankit Vachhani
Screenshot of Ivo Abraham, PhD, RN, during a video interview
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo